Associated Papers
Neoantigenic properties of TP53 variants influence cancer risk in individuals with Li-Fraumeni syndrome.
Montellier E et al.
Ebiomedicine, 2026
TP53 variant clusters stratify phenotypic diversity in germline carriers and reveal an osteosarcoma-prone subgroup.
Fischer NW et al.
Nature Communications, 2025
Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations.
Funk JS et al.
Nature Genetics, 2025
Clustering of TP53 variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndrome.
Montellier E et al.
Iscience, 2024
Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer.
Mezquita L et al.
British Journal of Cancer, 2024
Clinical and functional analysis of the germline TP53 p.K164E acetylation site variant.
Pinto EM et al.
Cold Spring Harbor Molecular Case Studies, 2023
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.
Nannya Y et al.
Blood Advances, 2023
GINS4 suppresses ferroptosis by antagonizing p53 acetylation with Snail.
Chen L et al.
Proceedings of the National Academy of Sciences of the United States of America, 2023
Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types.
Sasaki K et al.
Scientific Reports, 2023
Synthetical lethality of Werner helicase and mismatch repair deficiency is mediated by p53 and PUMA in colon cancer.
Hao S et al.
Proceedings of the National Academy of Sciences of the United States of America, 2022
Mutant p53K120R expression enables a partial capacity to modulate metabolism.
Monti P et al.
Frontiers in Genetics, 2022
An unexpected role for Dicer as a reader of the unacetylated DNA binding domain of p53 in transcriptional regulation.
Yang X et al.
Science Advances, 2021
An unexpected role for p53 in regulating cancer cell-intrinsic PD-1 by acetylation.
Cao Z et al.
Science Advances, 2021
mTOR inhibition acts as an unexpected checkpoint in p53-mediated tumor suppression.
Kon N et al.
Genes & Development, 2021
Insights into the limitations of transient expression systems for the functional study of p53 acetylation site and oncogenic mutants.
Bruer M et al.
Biochemical and Biophysical Research Communications, 2020
The role of acetylation sites in the regulation of p53 activity.
Wang Y et al.
Molecular Biology Reports, 2020
Abrogation of FBW7α-dependent p53 degradation enhances p53's function as a tumor suppressor.
Tripathi V et al.
The Journal of Biological Chemistry, 2019
Inhibiting p53 Acetylation Reduces Cancer Chemotoxicity.
Zheng S et al.
Cancer Research, 2017
Germ-line and somatic EPHA2 coding variants in lens aging and cataract.
Bennett TM et al.
Plos One, 2017
The role of Dbf4-dependent protein kinase in DNA polymerase ζ-dependent mutagenesis in Saccharomyces cerevisiae.
Brandão LN et al.
Genetics, 2014
Functional analysis of the acetylation of human p53 in DNA damage responses.
Chung SK et al.
Protein & Cell, 2014
TP53 mutations in human cancer: database reassessment and prospects for the next decade.
Leroy B et al.
Human Mutation, 2014
p53 inhibits autophagy by interacting with the human ortholog of yeast Atg17, RB1CC1/FIP200.
Morselli E et al.
Cell Cycle (georgetown, Tex.), 2011
Fission yeast Hsk1 (Cdc7) kinase is required after replication initiation for induced mutagenesis and proper response to DNA alkylation damage.
Dolan WP et al.
Genetics, 2010
A DNA replication mechanism for generating nonrecurrent rearrangements associated with genomic disorders.
Lee JA et al.
Cell, 2007